AI illustration · not actual product photoDetails from the source.
This catalogue entry records Survodutide, 10 mg × 10 vials (SKU SUR10), using the supplied source listing. The cited dossier describes: Human research has studied weight outcomes in adults with overweight or obesity and biopsy-based liver outcomes in MASH with fibrosis. A phase 3 MASH/fibrosis study remained recruiting as of 2026-10-28. Separate preclinical studies used cell assays and mice; do not present those findings as human evidence. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- SUR10
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 4
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The price list gives the exact label ‘Survodutide’ (SKU SUR10; specification *10vials). The named investigational molecule is a synthetic acylated peptide that activates both the glucagon and GLP-1 receptors. The catalogue does not verify that this vial contains that molecule or identify its manufacturer, formulation, lot, purity, or jurisdiction. Do not classify the supplier-specific item as compounded or research-only without documentation.
Biological mechanism
Survodutide is designed to activate glucagon and GLP-1 receptors involved in metabolic regulation. Cell-based and animal work characterized receptor activity and weight-related effects, but those preclinical findings do not establish the same effects in people. The clinical contribution of each pathway remains under study. [3] [4] [5]
Research focus
Human research has studied weight outcomes in adults with overweight or obesity and biopsy-based liver outcomes in MASH with fibrosis. A phase 3 MASH/fibrosis study remained recruiting as of 2026-10-28. Separate preclinical studies used cell assays and mice; do not present those findings as human evidence. [3] [4] [5] [6]
Potential applications in the evidence
Investigated, not established uses include body-weight outcomes in adults with overweight or obesity and histologic MASH/fibrosis outcomes. These are areas of clinical research on the investigational molecule, not proven applications or claims for the catalogue vial. [3] [5]
Human evidence
In the 76-week phase 3 SYNCHRONIZE-1 trial of 725 adults with overweight or obesity without diabetes, mean weight change under the treatment-regimen analysis was −12.2% and −13.0% in the two survodutide groups versus −5.4% with placebo. In a separate 48-week phase 2 study of 293 adults with MASH and fibrosis, improvement in MASH without worsening fibrosis was reported in 47%, 62%, and 43% across survodutide groups versus 14% with placebo. The liver result is an intermediate histologic trial outcome, not proof of long-term benefit. Neither study tested or verified the SUR10 vial. [3] [5]
Known and potential effects
Gastrointestinal symptoms were the most common adverse events in the phase 3 obesity trial, reported in 80.9% and 89.7% of the survodutide groups versus 47.9% with placebo. In the phase 2 MASH study, nausea (66% vs 23%), diarrhea (49% vs 23%), and vomiting (41% vs 4%) were more frequent with survodutide than placebo; serious adverse events were 8% versus 7%. These trial observations do not establish the effects or safety of the catalogue vial. [3] [5]
Safety and contraindications
No FDA-approved survodutide prescribing information was identified to provide a formal contraindication list. Trial adverse-event data are limited to studied participants, trial formulations, and finite follow-up; uncommon or longer-term risks remain uncertain. FDA warns that unapproved products containing survodutide have been sold directly to consumers under false ‘research purposes’ or ‘not for human consumption’ labels and may be of unknown quality. This warning does not establish that this particular catalogue item is one of those products. [2] [3] [5]
U.S. FDA / regulatory status
As of 2026-10-30, no U.S. FDA approval for survodutide was identified. FDA’s 2026 novel-drug approvals page, current through 2026-10-20, does not list it; FDA identifies Drugs@FDA as the searchable record of approved human drug products. Survodutide is described in the phase 3 publication as investigational. Approval, designation, or evidence for an active ingredient or a particular branded formulation would not establish approval or quality for this supplier-specific vial. The catalogue does not provide enough information to verify the vial’s regulatory status in any jurisdiction. [1] [3]
Evidence limitations
Human evidence includes phase 3 obesity results and phase 2 MASH findings, but does not establish long-term outcomes or safety. The phase 2 MASH result requires phase 3 confirmation. Preclinical cell and animal findings are not human evidence. The cited studies were sponsor-funded and used trial materials, not the identified catalogue item. The price list supplies no manufacturer, lot, formulation source, ingredient sequence, certificate of analysis, jurisdiction, or approval documents, so the exact vial identity remains unverified. [3] [4] [5] [6]
Supporting sources
- Novel Drug Approvals for 2026 U.S. Food and Drug Administration · Official regulatory database/list. Supports: Supports the statement that survodutide is absent from the FDA 2026 novel-drug approvals list current through 2026-10-20.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration · Safety communication. Supports: Supports the safety/regulatory caution: FDA warns products containing survodutide have been sold under false research-use disclaimers and may be of unknown quality; does not identify this catalogue vial.
- Survodutide Once Weekly for the Treatment of Adults with Obesity New England Journal of Medicine · Peer-reviewed phase 3 randomized clinical trial. Supports: Supports investigational status, dual-receptor mechanism, human obesity trial outcomes and reported gastrointestinal adverse events.
- BI 456906: Discovery and Preclinical Pharmacology of a Novel GCGR/GLP-1R Dual Agonist with Robust Anti-Obesity Efficacy Molecular Metabolism / PubMed Central · Peer-reviewed preclinical pharmacology study. Supports: Supports that BI 456906 is an acylated peptide dual agonist and documents in-vitro and animal work, which is explicitly distinguished from human evidence.
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis New England Journal of Medicine / PubMed · Peer-reviewed phase 2 randomized clinical trial. Supports: Supports the MASH/fibrosis research focus, phase 2 human histology findings and adverse-event rates.
- LIVERAGE: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis ClinicalTrials.gov, U.S. National Library of Medicine · Official clinical trial registry. Supports: Supports ongoing phase 3 MASH/fibrosis research and the record status and estimated completion as of its 2026-10-28 update.